OHSU

Atul Deodhar, M.D., M.R.C.P.

Head Shot of Atul Deodhar
Specialty:
Rheumatology
Special Interest:
Arthritis & Rheumatic Diseases
Accepting Patients:
Yes
Languages:
English, Hindi

Biography

Dr. Deodhar specializes in Rheumatology and autoimmune diseases and takes care of patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, systemic lupus, osteoporosis, fibromyalgia, etc. His research interests are spondyloarthritis (ankylosing spondylitis, psoriatic arthritis), novel treatments for inflammatory arthritis, and osteoporosis in inflammatory arthritides. Dr. Deodhar is the medical director of Rheumatology Clinics at OHSU. He is fluent in Hindi and Marathi. He is married with one daughter, and enjoys traveling, hiking and skiing.

Professional Education

  • Degree:
    MBBS: university of Pune, India, 1980<br />MD: University of Pune, India, 1984<br />DNB: New Delhi, 1987<br />MRCP: Royal College of Physicians, London, 1990<br />MD: University of Bath, England, 1996
  • Residency:
    KEM Hospital, Pune, India
  • Fellowship:
    Rheumatology: Royal Cornwall Hospital, Truro, England;  Oregon Health & Science University, Portland, OR
 

Email this page Print this page Twitter Facebook Digg More Options

Provider Referral Line

503 494-8637

Clinics

Arthritis & Rheumatic Diseases (Adult)

I see patients at:

Physicians Pavilion

Insurance Information

OHSU accepts most insurance plans

Insurance Information

Clinical Trials

The following clinical trials are currently accepting new participants:

A multicenter study of the prevalence of Axial Spondyloarthritis (SpA) in the United States Among subjects with chronic back pain and other SpA-related features.

A randomized, double-blind, placebo-controlled, multicenter study of secukinumab to demonstrate the efficacy at 16 weeks and to assess the long term safety, tolerability and efficacy up to 2 years in patients with active Ankylosing Spondylitis

A randomized, double-blind, placebo-controlled study of secukinumab to demonstrate the efficacy at 24 weeks and to assess the safety, tolerability and long term efficacy up to 2 years in patients with active rheumatoid arthritis who have an inadequate response to anti-TNFa agents(AIN457).

A Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Etanercept in Subjects with Moderately Active Rheumatoid Arthritis Despite DMARD Therapy

Search all studies